We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 16, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , Allogene Therapeutics (ALLO - Free Report) and Corcept Therapeutics (CORT - Free Report) .
Here are highlights from Friday’s Analyst Blog:
FDA Approves Pfizer's (PFE - Free Report) Braftovi + Mektovi for Lung Cancer
Pfizer announced that the FDA had approved its supplemental new drug applications (sNDAs) seeking label expansion for Braftovi (encorafenib) + Mektovi (binimetinib) in adult patients with BRAF V600E-mutant metastatic non-small cell lung cancer (“NSCLC”).
The approvals were based on data from the ongoing phase II PHAROS study, which evaluated Braftovi plus Mektovi in patients with BRAF V600E-mutant metastatic NSCLC. In the study, PHAROS met its primary endpoint of objective response rate.
Following the label expansion, the Braftovi/Mektovi combination is approved for two indications in the United States. The combination is already approved for treating adult patients with BRAF V600E or V600K mutated metastatic melanoma. Braftovi, in combination with cetuximab, is also approved to treat adult patients with BRAF V600E-mutated metastatic colorectal cancer.
Per management estimates, NSCLC accounts for nearly 80-85% of all lung cancer cases. A BRAF V600E mutation occurs in around 2% of all NSCLC cases. To counter such specific types of cancers, personalized therapies like Braftovi + Mektovi are required, which can address a genetically changed NSCLC indication.
Shares of Pfizer have lost 35.8% so far this year against the industry’s 8.5% growth.
Braftovi and Mektovi were added to Pfizer’s oncology portfolio with the acquisition of Array Biopharma in 2019.
Pfizer has the largest number of new product and indication launches planned for 2023, most of which are expected to occur in the second half of the year. Pfizer is more than halfway to its goal of launching 19 new products or indications in 18 months (all non-COVID indications), which are expected to generate around $20 billion in sales by 2030. Two-thirds of these products have blockbuster potential, according to Pfizer.
Pfizer RSV vaccine, Abrysvo, was approved to help protect older adults, as well as infants (through maternal immunization) in the United States in 2023. In August, the FDA approved Elrexfio, a BCMA-CD3-targeted bispecific antibody for relapsed/refractory multiple myeloma. In June, the FDA approved Litfulo, its JAK3 inhibitor for treating severe alopecia areata and Ngenla, a long-acting once-weekly pediatric growth hormone deficiency treatment. In March, the agency approved the company’s migraine nasal spray, Zavzpret, for use in adults.
These approvals will likely boost the company’s top line, which has been suffering a plunge due to a fall in demand for COVID-19 products.
In the past 60 days, estimates for Allogene Therapeutics’ 2024 earnings per share narrowed from $2.23 to $2.21. Year to date, shares of Allogene Therapeutics have lost 52.9%.
Earnings of Allogene Therapeutics beat estimates in three of the trailing four quarters while meeting the mark on one occasion, witnessing an average earnings surprise of 3.93%. In the last reported quarter, Allogene Therapeutics’ earnings beat estimates by 10.17%.
In the past 60 days, estimates for Corcept Therapeutics’ 2023 earnings per share increased from 75 cents to 78 cents. During the same period, the earnings estimate per share for 2024 has improved from 81 cents to 83 cents. Year to date, shares of Corcept Therapeutics have risen 36.0%.
Earnings of Corcept Therapeutics beat estimates in two of the trailing four quarters while missing the mark on the other two occasions, witnessing an average earnings surprise of 6.99%. In the last reported quarter, Corcept Therapeutics’ earnings beat estimates by 66.67%.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights Pfizer, Allogene Therapeutics and Corcept Therapeutics
For Immediate Release
Chicago, IL – October 16, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , Allogene Therapeutics (ALLO - Free Report) and Corcept Therapeutics (CORT - Free Report) .
Here are highlights from Friday’s Analyst Blog:
FDA Approves Pfizer's (PFE - Free Report) Braftovi + Mektovi for Lung Cancer
Pfizer announced that the FDA had approved its supplemental new drug applications (sNDAs) seeking label expansion for Braftovi (encorafenib) + Mektovi (binimetinib) in adult patients with BRAF V600E-mutant metastatic non-small cell lung cancer (“NSCLC”).
The approvals were based on data from the ongoing phase II PHAROS study, which evaluated Braftovi plus Mektovi in patients with BRAF V600E-mutant metastatic NSCLC. In the study, PHAROS met its primary endpoint of objective response rate.
Following the label expansion, the Braftovi/Mektovi combination is approved for two indications in the United States. The combination is already approved for treating adult patients with BRAF V600E or V600K mutated metastatic melanoma. Braftovi, in combination with cetuximab, is also approved to treat adult patients with BRAF V600E-mutated metastatic colorectal cancer.
Per management estimates, NSCLC accounts for nearly 80-85% of all lung cancer cases. A BRAF V600E mutation occurs in around 2% of all NSCLC cases. To counter such specific types of cancers, personalized therapies like Braftovi + Mektovi are required, which can address a genetically changed NSCLC indication.
Shares of Pfizer have lost 35.8% so far this year against the industry’s 8.5% growth.
Braftovi and Mektovi were added to Pfizer’s oncology portfolio with the acquisition of Array Biopharma in 2019.
Pfizer has the largest number of new product and indication launches planned for 2023, most of which are expected to occur in the second half of the year. Pfizer is more than halfway to its goal of launching 19 new products or indications in 18 months (all non-COVID indications), which are expected to generate around $20 billion in sales by 2030. Two-thirds of these products have blockbuster potential, according to Pfizer.
Pfizer RSV vaccine, Abrysvo, was approved to help protect older adults, as well as infants (through maternal immunization) in the United States in 2023. In August, the FDA approved Elrexfio, a BCMA-CD3-targeted bispecific antibody for relapsed/refractory multiple myeloma. In June, the FDA approved Litfulo, its JAK3 inhibitor for treating severe alopecia areata and Ngenla, a long-acting once-weekly pediatric growth hormone deficiency treatment. In March, the agency approved the company’s migraine nasal spray, Zavzpret, for use in adults.
These approvals will likely boost the company’s top line, which has been suffering a plunge due to a fall in demand for COVID-19 products.
Zacks Rank & Stocks to Consider
Pfizer currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks are Allogene Therapeutics and Corcept Therapeutics, each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for Allogene Therapeutics’ 2024 earnings per share narrowed from $2.23 to $2.21. Year to date, shares of Allogene Therapeutics have lost 52.9%.
Earnings of Allogene Therapeutics beat estimates in three of the trailing four quarters while meeting the mark on one occasion, witnessing an average earnings surprise of 3.93%. In the last reported quarter, Allogene Therapeutics’ earnings beat estimates by 10.17%.
In the past 60 days, estimates for Corcept Therapeutics’ 2023 earnings per share increased from 75 cents to 78 cents. During the same period, the earnings estimate per share for 2024 has improved from 81 cents to 83 cents. Year to date, shares of Corcept Therapeutics have risen 36.0%.
Earnings of Corcept Therapeutics beat estimates in two of the trailing four quarters while missing the mark on the other two occasions, witnessing an average earnings surprise of 6.99%. In the last reported quarter, Corcept Therapeutics’ earnings beat estimates by 66.67%.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.